Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
A legfontosabb adatok
- Ki végzi
- Institute of Hematology & Blood Diseases Hospital, China
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 160 fő, tervezett
- Kezdés
- 2026. jan. 28.
- Várható befejezés
- 2028. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Daratumumab(Anti-CD38 Monoclonal Antibody)
- Rituximab
- A regiszteradat frissítve
- 2026. február 11.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with primary immune thrombocytopenia (ITP, a low platelet count caused by the immune system) whose steroid treatment did not work or stopped working. It compares rituximab plus daratumumab with rituximab alone.
- Életkor
- 18 years or older
- Nem
- Male or female
- A betegség stádiuma
- Primary ITP diagnosed at least three months before joining. ECOG performance status of 2 or less (able to care for yourself). Heart function NYHA class 2 or less.
- Korábbi kezelés
- Glucocorticoid (steroid) treatment must have failed, stopped working, or the disease came back. Emergency ITP treatment must have ended at least 2 weeks before the first dose. Azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus and similar drugs must be stopped at least 4 weeks before. Rituximab or other CD20 antibodies must have been stopped for more than 6 months. Spleen removal must be more than 6 months ago. Steady glucocorticoids (≤0.5 mg/kg prednisone or equivalent) or TPO receptor agonists are allowed if stable for at least 4 weeks.
- Biomarker vagy leletérték
- Platelet count below 30×10^9/L within 48 hours before the first dose, and in at least two tests at least 1 week apart during screening. Liver and kidney tests below 1.5 times the upper limit of normal.
A részvétel fő kizáró okai
- HIV positive, or uncontrolled active infection such as hepatitis B, hepatitis C, cytomegalovirus, EB virus or syphilis
- Severe bleeding, such as bleeding in the brain or gut, or coughing up blood
- Blood clot diseases, uncontrolled heart disease, or serious organ disease such as cancer or organ failure
- Past allogeneic stem cell transplant or organ transplant
- Pregnant or breastfeeding, or taking antiplatelet drugs
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 years, male or female
- Before enrollment, the subjects have been clinically diagnosed with primary immune thrombocytopenia for no less than three months according to the American Society of Hematology guidelines 2011 Evidence-Based Practice Guideline (Neunert et al. 2011) or the International Consensus Report for the Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as applicable locally
- Subjects with a platelet count of <30×10\^9/L within the 48 hours prior to the first dose of the study drug;The platelet count of at least two separate assessments (at least 1 week apart) <30×10\^9/L during the screening visit
- Patients have failed glucocorticoid therapy (either due to inefficacy, efficacy could not be maintained, or relapse)
- Previous emergency treatment for ITP (e.g., methylprednisolone, platelet, gamma globulin infusion) must have been completed at least 2 weeks before the first dose
- Hepatic and renal function (e.g., alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine) <1.5 times the upper limit of normal (ULN)
- ECOG performance status score of ≤2
- Cardiac function: New York Heart Association (NYHA) class ≤2
- Enrollment of subjects receiving maintenance therapy is permitted, including glucocorticoids (≤0.5 mg/kg of prednisone or equivalent) or TPO receptor agonists, but the concomitant medication must have been stable for a minimum of 4 weeks prior to the initial infusion of the study drug; Azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first dose; CD20 monoclonal antibody such as rituximab must have been stopped for more than 6 months; the interval between splenectomy and first administration need to be more than 6 months
- For fertile female patients, a negative pregnancy test result is required. Fertile female and male patients must use effective contraception separately during the study and for 90 days after the cessation of study drug treatment
- Subjects comprehensively understand and can adhere to the study protocol requirements and willingly signed the informed consent form
Ki nem vehet részt
- Those who have received allogeneic stem cell transplantation or organ transplantation in the past
- Patients taking antiplatelet drugs at the same time
- Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases
- HIV positive
- Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive
- Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
- At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled
- Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis
- atients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up
- Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.)
- Patients with septicemia or other irregular severe bleeding
- Subjects with a known allergy to medications were used in the trial or excipients
- Any other conditions unsuitable for participation in this study, as assessed by the investigator
- Patients whose toxic symptoms caused by pre-trial treatment have not disappeared
- Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This randomized, open-label study aim to compare the efficacy and safety of rituximab combining anti-CD38 monoclonal antibody with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.
A vizsgálat 2 csoportja
- rituximab combined with Daratumumab(anti-CD38 monoclonal antibody)A vizsgált kezelés
Rituximab (375mg/m2) was given once (day1) and a Daratumumab (16mg/kg) was given four times (day8,15,22,29).
Kezelés: Daratumumab(Anti-CD38 Monoclonal Antibody) és Rituximab
- rituximabMár használt kezelés, összehasonlításként
Rituximab (375mg/m2) was given once.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Open-label Study To Compare The Efficacy And Safety Of Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in ITP Patients Who Failed or Relapsed After Glucocorticoid Therapy
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. február 11.